Green Car Stock News; EVCARCO (OTCBB: EVCA) to Sell Class 3-5 Commercial Compressed Natural Gas Powered Trucks at Its Green Auto Dealerships

FT. WORTH, TX - February 15, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO (OTCBB: EVCA) announced today that it will sell CNG powered Foton MD 3000 medium-duty class 3-5 trucks at its green auto dealerships. Foton Motor Co. is the largest commercial vehicle manufacturer in China, its existing assets are in excess of 5 Billion Dollars U.S. and they have a staff of 28,000 employees. Foton has the capacity to produce up to 26,000 units of the Foton MD 3000 medium-duty class 3-5 trucks a year.

The MD 3000 and LD1000 are versatile for multi-use applications and are equipped with cargo delivery bodies. The vehicle's chassis and Euro-style cab design allows for easy multi-conversions for uses such as street sweepers and refuse collection. The truck will allow businesses and municipalities to have a high quality, environmentally friendly, domestically produced clean natural gas solution for all of their truck needs.
Mack Sanders, CEO of EVCARCO, stated, "The MD 3000 and LD1000 CNG powered truck will allow our green auto dealerships to enter the commercial sales arena with a high quality versatile environmentally friendly medium duty truck, DOT compliant and with a full warranty. We expect to receive the first CNG powered Foton 3000 next month. Government support and mandates, which have been the key to the adoption of natural-gas vehicles in the U.S. recently, has confirmed our vision. Our team has worked diligently for some time with the manufacturer's distributor on the development of this project and we are pleased with the results."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. We live in the communities we work in; our corporate culture reflects the greening aspirations of our customers. Our dealerships are not just a place to buy a vehicle; they are a warm embrace of eco-culture, a place where like minded individuals can interact while getting a quick AltEng refill on their way to work.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax

Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).

Young YouTube Musician Raises Funds and Awareness for Safe House at Pine Ridge Reservation

February 15, 2011 (Investorideas.com Newswire)- Investorideas.com and its non-profit newswire interviews Illinois based musician, Dan Ross, as he nears his date for his 2000 mile walk across America for peace. Investorideas.com finds out what motivates a musician known as �Goofy Guitarist� on YouTube.com to walk for the people of Pine Ridge.

On April 15, Dan Ross begins his walk from Chicago, Illinois to the Oregon coast.
Funds raised from his walk will be donated to the youth of the Pine Ridge Reservation and the non-profit ONE Spirit.
Pine Ridge is an Oglala Sioux Native American reservation located in South Dakota. Pine Ridge is the eighth-largest reservation in the United States, and is also sadly, the poorest
Q: Investorideas.com
Dan, you walk for peace is in Synchrodestiny with the universe now as we have witnessed one of the most dramatic and peaceful protests by a people in Egypt.
Can you tell us what motivated and inspired you to take on such a challenging endeavor?
A: Dan Ross
Honestly, I was watching "Forrest Gump" one night during the fall of 2010 when I was first struck with the idea to walk across 2/3 of the country. For those of you who are unfortunate enough not to have seen the movie (because it's a good one!), the main character spontaneously decides to run across the entire country, and it is certainly an inspiring moment in the film. Before that night, I had already planned on moving out of my hometown in 2011, in an effort to broaden my horizons and gain a new clarity of mind so that I might discover what I'd like to pursue in life; I just wasn't sure exactly where I would go or how I'd get there. So I would say that I was primed, ready, and waiting for a good idea to come along. All I needed was a spark of inspiration.
What motivates me to take on such a challenging endeavor is the fact that it IS a challenge. I enjoy pushing myself, if for no other reason than to test my own potential. Also, I believe traveling is one of the wisest things a person can do with their time and money- it allows you to learn things which cannot be taught. The possibilities of what I can learn from this journey are more than enough to motivate me to do it.
Q: Investorideas.com
You have chose the youth of the Pine Ridge Reservation and the building of the Safe House and youth center as your non-profit to dedicate this to. A white youth from Illinois dedicating his walk to the native youth at Pine Ridge is an unexpected storyline; can you tell us how that came to be?
A: Dan Ross
Once I was certain that I would walk to the ocean in 2011, I began to think that maybe someone besides myself could benefit from this whole thing. After quite a bit of brainstorming, I was still unable to decide what cause I would walk for. Then, amidst the planning of my route, I noticed I would be walking right through the Pine Ridge Reservation in South Dakota, a place which I knew nothing about at the time. So I did a little research, and the information I found was startling and overwhelming- unemployment estimated at 87%, life expectancy of about 50 years, 90% living below the federal poverty level, and teenage suicide rates 3 1/2 times the national average. I couldn't believe that this place was located practically right in the middle of the United States. The fact that I was unaware of the situation at Pine Ridge makes me think that most others living in this country are unaware, as well. From this point on, I was sure that I had found a just cause.
After notifying One Spirit that I would like to help, we decided I should dedicate the walk primarily to the youth on the reservation. If you provide the younger generation with a safer childhood, and more opportunities to learn and grow, it becomes likely that they will want to take action to help the next generation in the same way. If all a child knows growing up is poverty, it's easier to turn to drugs and/or gangs as a way out. I want to help show them something better.
Q: Investorideas.com
Listening to your music, and you are really good by the way, one of your songs is called "Taking action ". Is that how you live your life?
A: Dan Ross
I will admit that I am not always "taking action" in my life, and that I don't mean to either. I like taking the time to think things through and plan carefully to ensure that when I do take action, I get results. However with that being said, there has been a lack of action being taken in my life this past year. I suppose I still don't know what I want to be when I grow up, but wait, I'm already grown up! 2010 seemed to fly by, and my mind is clouded with uncertainty regarding where I'm going in life. By embarking on this walk, I will take action to gain a new perspective on things, and help the Lakota people in the process.
Q: Investorideas.com
We saw with Egypt how the young protesters made effective use of Facebook.com and Twitter.com to get their message and story out. Do you see it playing a big role in your walk and getting donations and awareness?
A: Dan Ross
Facebook and Twitter are certainly crucial in raising awareness for the walk. One Spirit and myself have already established contact over Facebook with people in other states who are eager to help coordinate the walk and spread the word. Throughout the walk I'll be posting updates on both Facebook and Twitter about where I am and what I'm doing so people can follow along. So if you're interested, join the group! And invite your friends!
Q: Investorideas.com
What is your goal in terms of dollar amount you hope to raise with your walk and how can people donate and support what you are doing?
A: Dan Ross
I would rather not set a specific $ amount for a goal, as the main purpose of the walk is not only to raise money for the youth center One Spirit plans to build on the reservation, but also to raise awareness of the conditions at Pine Ridge. People who have never even heard of the place (like myself before this whole thing got started) need to know about it, because it's right here in America. Even if all I accomplished at the end of the walk was telling everyone about it, I would still consider it a success.
To donate, you can become a sponsor and give a dollar amount per mile, per state, or for the entire trip by visiting the One Spirit website at <www.nativeprogress.org>. Donations can be made through the website using Paypal, or by mailing a check or money order to :

One Spirit
P.O. Box 3209
Rapid City, SD 57709

Additional information regarding the walk can easily be found at the website. Even if you don't have much to give, every little bit counts and is greatly appreciated!
Q: Investorideas.com
Any inspirational words for our readers in closing?
A: Dan Ross
Travel. Go places. Meet people. See and do things you've never seen and done before. It will make you more worldly, which makes you wiser. Staying in the same place for too long without ever leaving, not even for a small weekend trip, will cause your world to shrink around you, and you'll shrink with it. So broaden your horizons, see the world, and be aware of what's going on both near and far and you will be better for it.
http://www.facebook.com/upgradeaccount.php
Follow Dan On Facebook
Learn more about Dan's mission at his facebook group:
Dan Ross Walks to the Pacific
Hear Dan's Music:
http://www.youtube.com/user/goofyguitarist11
ONE Spirit is proud to be able to offer a way for you to directly help a Lakota child, family, or elder in need.
http://www.nativeprogress.org/
ONE Spirit is a Native American service organization founded to assist and support American Indians. We are proud to think of our organization, ONE Spirit, as a group of people who exchange friendship, with American Indians. at present our focus is the Lakota Sioux in South Dakota. We invite you to become part of ONE Spirit's network of sponsors, partners, friends and volunteers, to dream with the Lakota people a new dream - and to help the dreams come alive!
Mission
The ONE Spirit Mission is to assist the Lakota people in preserving and revitalizing the Lakota culture, language, and self-sufficiency while meeting the basic needs of Lakota families, children, and elders. We strive to cultivate an intercultural relationship that recognizes that we are all related and that American Indians are an equal and valued part of our society.
Follow One Spirit on Twitter
Follow One Spirit's Blog
Jeri Baker
ONE Spirit Executive Director
570-460-6567
jbaker@nativeprogress.org
Diane Capalario
ONE Spirit Assistant Director
dcapalario@nativeprogress.org
About Investorideas.com
Investor ideas that can change the world
Learn more about the non - profits we support and endorse
http://www.investorideas.com/About/Newsletter/CharitableCauses.asp
Contact Investorideas.com
800 665 0411
Dvanzant@investorideas.com

Natural Gas Vehicle Stock News; Clean Energy Fuels, EVCARCO

February 15, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on recent clean energy news and natural gas vehicle news for investors following the sector. EVCARCO (OTCBB: EVCA) reports it will sell Class 3-5 Commercial Compressed Natural Gas Powered Trucks at Its Green Auto Dealerships and Clean Energy Fuels (Nasdaq:CLNE) announces it will report Fourth Quarter 2010 Financial Results on March 10th.

Natural Gas Vehicle Sector Snapshot
Clean Energy Fuels Corp. (Nasdaq:CLNE) trading at $12.19, up 0.02 (0.16%) 1:19PM EST
EVCARCO (OTCBB: EVCA) trading at .0621
WESTPORT INNOVATIONS INC. ( Toronto: WPT.TO) trading at $15.27, down 0.21 (1.36%)
Market Snapshot

• Dow 12,223.88 -44.31 -0.36%
• Nasdaq 2,808.74 -8.44 -0.30%
• S&P 500 1,328.26 -4.06 -0.30%
• 10 Yr Bond (%) 3.6290% +0.0150
• Oil 84.08 -0.73 -0.86%
• Gold 1,372.40 +7.80 +0.57%

Company Snapshots
EVCARCO (OTCBB: EVCA) (www.evcarco.com) is an automotive retail group dedicated to deploying a franchised coast-to-coast network of environmentally friendly dealerships and vehicles.
About Clean Energy Fuels (Nasdaq:CLNE)
Clean Energy fuels more than 19,900 vehicles at 211 strategic locations across the United States and Canada with a broad customer base in the refuse, transit, trucking, shuttle, taxi, airport and municipal fleet markets. It owns (70%) and operates a landfill gas facility in Dallas that produces renewable methane gas, or biomethane, for delivery in the nation's gas pipeline network. It owns and operates LNG production plants in Willis, Texas and Boron, Calif. with combined capacity of 260,000 LNG gallons per day and that are designed to expand to 340,000 LNG gallons per day as demand increases. NorthStar, a wholly owned subsidiary, is the recognized leader in LNG/LCNG (liquefied to compressed natural gas) fueling system technologies and station construction and operations. BAF Technologies, Inc., a wholly owned subsidiary, is a leading provider of natural gas vehicle systems and conversions for taxis, vans, pick-up trucks and shuttle buses. IMW Industries, Ltd., a wholly owned subsidiary based in Canada, is a leading supplier of compressed natural gas equipment for vehicle fueling and industrial applications with more than 1,000 installations in 24 countries.
Recent News
Natural Gas News; EVCARCO (OTCBB: EVCA) to Sell Class 3-5 Commercial Compressed Natural Gas Powered Trucks at Its Green Auto Dealerships
Visit this company: www.evcarco.com
FT. WORTH, TX - February 15, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO (OTCBB: EVCA) announced today that it will sell CNG powered Foton MD 3000 medium-duty class 3-5 trucks at its green auto dealerships. Foton Motor Co. is the largest commercial vehicle manufacturer in China, its existing assets are in excess of 5 Billion Dollars U.S. and they have a staff of 28,000 employees. Foton has the capacity to produce up to 26,000 units of the Foton MD 3000 medium-duty class 3-5 trucks a year.
Full news: http://www.investorideas.com/news/2011/energy/02151.asp
Clean Energy Fuels to Report Fourth Quarter 2010 Financial Results on March 10
Visit this company: www.cleanenergyfuels.com
SEAL BEACH, Calif. - February 15, 2011 (Investorideas.com renewable energy/green newswire) - Clean Energy Fuels Corp. (Nasdaq:CLNE - News) announced today it will release financial results for the fourth quarter and fiscal year ended December 31, 2010 after market close on Thursday, March 10, followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). President and Chief Executive Officer of Clean Energy Andrew J. Littlefair and Chief Financial Officer Rick Wheeler will host the call.
Full news: http://www.investorideas.com/news/2011/energy/02152.asp
Research green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks included range from LNG, Coal Bed Methane to exploration and producers in the sector. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description.
Renewable Energy Stocks Directory - Global Green and Renewable Energy Stocks Directory in PDF format includes over 1200 stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges . The directory features hyperlinks to stocks symbol(s), company’s URL and company’s description. The directory includes info and links on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure Stocks. For investors following green stocks, this is the most comprehensive global stock directory online.
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a former showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com

Gold Stocks; GOLD BULLION CONTINUES TO EXPAND MINERALIZED ZONES AT GRANADA PROPERTY

Vancouver, British Columbia - February 15, 2011 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) (the "Company" or "Gold Bullion") has received assay results for 56 diamond drill holes on its 100% owned Granada Gold Property near Rouyn-Noranda, Quebec. This includes the remaining assay results from the Phase 2, 25,000-metre drill program as well as initial holes of the 50,000 metre Phase-3 program. To date, over 13,000 metres of the Phase 3 program have been drilled. The goal of the current drill campaign is to test the continuity between the currently outlined Preliminary Block Model area and the eastern section of the LONG Bars Zone.

"We have now drilled an area 1,200 metres long and from 250 to 500 metres wide at the Granada property", commented Mr. Frank Basa, President and CEO of Gold Bullion Development Corp. "We are very pleased with the results to date and believe they will ultimately significantly expand the mineralized area in all directions outside the Preliminary Block Model."
Summary

• Outside of the Preliminary Block Model area, drilling has identified significant gold mineralization, many with long intercepts, in new structures in the NE Extension, SE Extension and Eastern Extension sectors.
• Consulting geologists at GENIVAR believe they may have intersected the extension of Vein #5 in the NE Waste Pile Sector
• Drills intersected high grade gold intervals in the Trail sector which may be related to a series of NNE trending fault zones. More work is required to validate this relationship.
• In the Preliminary Block Model area, Vein #2 has been extended along strike and down dip into the Vein #2 sector and numerous smaller parallel mineralized structures were identified to the north, in the hanging wall of the Vein.
• An aggressive drilling campaign continues to target the NE Extension, SE Extension and NE Waste Pile sectors.
• In March a drill will be moved to the Eastern part of the property to test the promising Aukeko target.

For increased clarity and ease of locating drill hole stations, the names of sector areas are being used to help describe drill hole locations with reference to the drill plan map which can be found on our website at http://www.GoldBullionDevelopmentCorp.com.
Mineralization at Granada is typically associated with finely disseminated pyrite and/or arsenopyrite. It is hosted within altered sericitized and silicified syenite feldspar porphyry sills and quartz vein stockwork and breccias as well as quartz-carbonate veinlets in the sedimentary rocks. These structures strike in an East-West direction and dip steeply to the north. Numerous parallel mineralized structures have been identified throughout the property.
Newly Delineated Structures
Gold Bullion's geological consultants, GENIVAR, report that additional structures have been intersected in the following sectors of the property; the NE Extension, the SE Extension and the Eastern Extension. Some drill hole highlights from these sectors include:

• Hole GR-10-113 in the NE Extension zone intersected a vein grading 162.75 g/t gold over 1.09 metres (starting 232.5-metres down hole).
• In the SE Extension area, holes GR-10-131 and 134 intersected what GENIVAR believes to be the same new structure. Hole GR-10-134 intersected 9.3-metres averaging 1.09 g/t gold within a 57-metre interval averaging 0.56 g/t gold. Hole GR-10-131 intersected 5-metres averaging 2.14 g/t gold within a 129-metre interval averaging 0.15 g/t gold.
• In the Eastern Extension zone, (where previously reported Hole GR-10-17 intersected 65.5 metres averaging 1.21 g/t gold), nine additional holes intersected long intervals of mineralization interspersed with narrow sections of higher grade. Hole GR-10-153 hit 135-metres averaging 0.62 g/t gold starting 3.9-metres down-hole. This included a 1-metre interval averaging 54.97 g/t starting 3.9-metres down-hole. Hole GR-10-145 cut a 45.9-metre interval averaging 0.82 g/t gold starting 31.3-metres down-hole that included a 1.5-metre interval that averaged 12.3 g/t gold.

NE Waste Pile Sector
In the NE Waste Pile Zone, GENIVAR believes it may have intersected the extension of Vein #5 in Holes GR-10-118 and GR-10-141. The Vein #5 outlined in the Preliminary Block Model Zone and based on this drill data may continue eastward. Hole GR-10-141 intersected 1.5-metres averaging 39.9 g/t gold, starting 40-metres down hole. This occurred in a larger mineralized envelope that averaged 0.52 g/t over 276 metres.
Trail Sector (Sector between Eastern Extension and Preliminary Block Model area)
A series of holes were drilled to test NNE trending faults identified in the Trail Sector. It is hypothesized that these faults may have acted as conduits for mineralizing fluids. Hole GR-10-117 cut a number of high grade intervals including:

• 2.4 metres averaging 22.5 g/t gold starting 4.6 metres down hole
• 1 metre averaging 14.95 g/t gold starting 76.5 metres down hole
• 1 metre averaging 15.65 g/t gold starting 107.5 metres down hole
• 18.5 metres averaging 2.3 g/t gold starting 150.5 metres down hole

These intervals, together with lower grade sections averaged 0.74 g/t gold over 198 metres.
Vein 2 Sector
A total of 16 new holes were drilled into the Vein #2 sector. Results have extended the vein down dip between 100 and 200 metres. In addition, numerous smaller parallel veins have been intersected in the hanging wall of Vein #2. All of these veins appear to be related to an altered feldspar porphyry.
Significant drill results include Hole GR-10-114 which intersected 177 metres averaging 0.51 g/t gold starting 3 metres down hole and Hole GR-10-54 which intersected 110 metres averaging 0.55 g/t gold starting 19 metres down hole.
Looking Ahead
Currently Gold Bullion has two drill rigs turning on the property as part of its Phase 3 drilling campaign. Five more holes will be collared in the NE Extension sector. An additional three holes will target the NE Waste Pile area and three holes will test the SE Extension sector (more if results warrant).
Later in March, Gold Bullion intends to drill test the Aukeko Shaft and the surrounding area. This target is situated on the eastern part of the property about 2 km east of the LONG Bars Zone. Historical data indicates that considerable visible gold was noted in the Aukeko vein at the bottom of the Aukeko shaft. Previous geological mapping detected numerous easterly striking syenite porphyry "dykes" and quartz veins similar to what is seen at the LONG Bars zone.
The Company plans to initiate a NI-43-101 resource estimate this summer once the majority of the Phase 3 drill results are received.
Please refer to the detailed drill map available on the Gold Bullion web site, www.GoldBullionDevelopmentCorp.com.
Widths reported in the preceding table are drill widths; true widths are unknown at this time. Assays are uncut, length-weighted average values.
QA/QC
Gold Bullion's NQ drill program and drill core sampling, including the quality assurance/quality control program, are supervised by GENIVAR, Gold Bullion's geological consultant. Core from the above holes was sent to ALS Chemex Labs in Val d'Or, Quebec, and Laboratoire Expert in Rouyn-Noranda, Quebec, for analysis. Gold was assayed by fire assay with additional metallics analysis done on samples where visible gold was identified. Analytical accuracy and precision are monitored by the analysis of reagent blanks and reference materials at both labs. Quality control is further assured by the insertion of blind certified standard reference material and blanks into the sample stream at regular intervals by Gold Bullion and GENIVAR personnel in order to independently assess analytical accuracy.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
Qualified Person
The scientific and technical information in this release was prepared under the supervision of Ms. Nicole Rioux, P. Geo., Genivar's senior geologist and a member of the Ordre des g�ologues du Qu�bec and a "qualified" person in accordance with National Instrument 43-101.
"Frank J. Basa"
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.

Biotech/Pharma Stock News; BioSante Presents Data Showing Female Sexual Dysfunction is a Significant Unmet Medical Need


LINCOLNSHIRE, Ill. - February 15, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products for the treatment of female sexual health, presented critical female sexual dysfunction market data at the ISSWSH (The International Society for the Study of Women�s Sexual Health) annual meeting. The data presented include results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

There are currently no FDA-approved therapeutic treatment options for women with HSDD. A significant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissatisfied with the non-FDA approved, off-label alternatives. The physicians indicated that they hear an average of 37 unsolicited inquiries per month from women regarding sexual dysfunction. Nationally, it is estimated that 4.1 million off-label testosterone prescriptions are filled annually.
"The need for an FDA-approved treatment to cope with this condition is astonishing, as stated by the physicians surveyed. This position also was strongly supported by the attendees at the ISSWSH meeting," said Michael C. Snabes, M.D., Ph.D., BioSante�s senior vice president of medical affairs. "It has been more than a decade since the FDA approved Viagra for the treatment of male sexual dysfunction; it is time women have a safe and effective option for the treatment of their sexual health." BioSante is developing LibiGel® (testosterone gel) for the treatment of HSDD in menopausal women. LibiGel is currently in three Phase III clinical studies to prove its safety and efficacy.
The physicians in the survey were asked their reaction to an unnamed therapeutic that fit LibiGel�s profile. An overwhelming 94% responded favorably, as long as it is proven to be safe. To that end, BioSante is conducting a Phase III multicenter cardiovascular and breast cancer safety study. BioSante reported at the ISSWSH meeting that with 2,869 women enrolled and over 3,000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent.
The survey, conducted independently for BioSante by Campbell Alliance Group, Inc., revealed sexual dysfunction to be one of the most common complaints received in these doctors� offices. The physicians described themselves as dissatisfied with the current lack of therapeutic options for HSDD, a loss of libido or sexual desire.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Mining Stocks; YALE Continues to Expand Silver Target at Los Amoles

February 15, 2011 (Investorideas.com Mining stocks Newswire) - Yale Resources Ltd. (TSX-V: YLL and Frankfurt: YAB) is pleased to report that field work at the Los Amoles Property continues to expand the main mineralized zone and has defined a vein system that has been traced on surface for approximately 800 metres along strike. Work at Los Amoles was done by Yale on behalf of Nature's Call, who has an option to earn a 70% interest in the property.

Sampling included:

• 2.0 metres grading 0.63 g/t gold and 698.6 g/t silver
• 6.0 metres averaging 0.33 g/t gold and 226.6 g/t silver
• including 2.0 metres grading 0.63 g/t gold and 497.3 g/t silver
• 1.0 metres grading 0.33 g/t gold and 496.8 g/t silver
• Dump material grading 0.24 g/t gold and 1,027.5 g/t silver

This latest field program was designed to prospect, map and sample the southern portion of the 1.0 by 2.5 kilometre main target area (see news releases dated April 15 and May 27, 2010). This work was successful in identifying an additional 20+ historic workings and Yale personnel successfully traced mineralization on surface for approximately 800 metres along strike. Sampling at irregular intervals along the strike length has returned gold and silver values.
In addition to strong values within the veins sampling has shown that proximal to the veins the host andesitic volcanic rocks often host silver mineralization in the order of 15 to 50 grams per tonne. A table of the highlight samples is provided below:
To date, greater than 45 historic workings and greater than 20 gold/silver veins have been identified within approximately 60% of the El Rosario target area that measures 1.0 by 2.5 kilometres. Another stage of fieldwork is planned in order to map and sample the remaining areas within the El Rosario target. This work will be done in advance of geophysics, which in turn, will be done to delineate priority locations for drilling.
About the Los Amoles Property:
The early stage wholly owned 16.3 square kilometre Los Amoles Property is located approximately 150 kilometres northeast of the Hermosillo, Sonora State, Mexico. The property is 10 kilometres northeast of the La Caridad Mine, operated by Grupo Mexico, which is one of the largest mining and processing complexes in Mexico.
Nature's Call has an option to earn a 70% interest in the property by paying to Yale US $ 50,000 (received), spending US $ 900,000 on exploration expenditures and issuing 1,000,000 shares (200,000 have been received) to Yale over three years.
Work performed to date by Yale has concentrated on an area (the Rosales area) that is on the eastern edge of a 4.0 by 2.75 km regional magnetic anomaly. Yale's interpretation is that the Rosales area represents silver-lead +/- gold veins that are distal to a porphyry system. The potential for this regional anomaly to reflect a buried porphyry has yet to be tested. Many of Sonora's most significant porphyry deposits are located within 70 km of the Los Amoles property.

Samples from Los Amoles were prepared and analyzed by IPL Inspectorate in their facilities in Mexico and Vancouver, respectively. Samples generally consisted of 1-3 kg of material. Gold and silver analyses were performed by 30 gram fire assay with an AA finish. Samples with greater than 100 g/t silver were re-assayed using gravimetric methods.
Ian Foreman, P.Geo., is Yale Resources� Qualified Person, as defined by National Instrument 43-101. The Los Amoles property is an early stage project that requires additional sampling and geological mapping to fully determine the project�s potential.

On behalf of the Board,
"Ian Foreman"
Ian Foreman, P.Geo.
President

For additional information on Yale Resources please call the Company at 604-678-2531.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.

Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.
Contact:
Yale Resources Ltd.
604-678-2531

Visit the YLL showcase profile at Investorideas.com
Request News and Info on YLL
Disclosure, Disclaimer/ YLL is a paid advertising client on Investorideas.com and our mining portals.

Natural Gas Stocks; EVCARCO (OTCBB: EVCA) to Sell Class 3-5 Commercial Compressed Natural Gas Powered Trucks at Its Green Auto Dealerships




FT. WORTH, TX - February 15, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO (OTCBB: EVCA) announced today that it will sell CNG powered Foton MD 3000 medium-duty class 3-5 trucks at its green auto dealerships. Foton Motor Co. is the largest commercial vehicle manufacturer in China, its existing assets are in excess of 5 Billion Dollars U.S. and they have a staff of 28,000 employees. Foton has the capacity to produce up to 26,000 units of the Foton MD 3000 medium-duty class 3-5 trucks a year.



The MD 3000 and LD1000 are versatile for multi-use applications and are equipped with cargo delivery bodies. The vehicle's chassis and Euro-style cab design allows for easy multi-conversions for uses such as street sweepers and refuse collection. The truck will allow businesses and municipalities to have a high quality, environmentally friendly, domestically produced clean natural gas solution for all of their truck needs.



Mack Sanders, CEO of EVCARCO, stated, "The MD 3000 and LD1000 CNG powered truck will allow our green auto dealerships to enter the commercial sales arena with a high quality versatile environmentally friendly medium duty truck, DOT compliant and with a full warranty. We expect to receive the first CNG powered Foton 3000 next month. Government support and mandates, which have been the key to the adoption of natural-gas vehicles in the U.S. recently, has confirmed our vision. Our team has worked diligently for some time with the manufacturer's distributor on the development of this project and we are pleased with the results."



For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.



EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. We live in the communities we work in; our corporate culture reflects the greening aspirations of our customers. Our dealerships are not just a place to buy a vehicle; they are a warm embrace of eco-culture, a place where like minded individuals can interact while getting a quick AltEng refill on their way to work.



This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.



Contact:



Investor Relations Contact:

Jack Eversull

The Eversull Group, Inc.

972-571-1624

214-469-2361 fax



Visit the EVCA showcase profile at Investorideas.com

Request News and Info on EVCA

Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals.(500,000 144 shares)



Published at www.Investorideas.com - Global research by sectors



If you have any questions regarding information in this press release please contact the company listed in the press release.



Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Microcap ETFs -- Bad Imitation of the Real Thing

Microcap Investor Functional Inspiration: Money and Innovation in the Microsphere

By Josh Levine
www.levinesmicrocapinvestor.com

February 14, 2011-New York, NY –

When it comes to microcap investing I'm a purist. I build our MicroCap Investor portfolio carefully
one stock at a time with the aim of generating tremendous profits from a relatively small selection
companies of developing high-value technologies in biotech, cleantech, and various emerging
technologies.

That's my preference, and while there are certainly other ways to participate in microcaps, there
is at least one strategy that makes absolutely no sense at all: Microcap ETFs. Money is a terrible
thing to waste, and these investments will definitely do just that.

The selling point for microcap ETFs is that they offer investors who don't have the time or
experience a ready means of participating in microcap investing. But as a Morningstar article
[LINK: http://news.morningstar.com/articlenet/article.aspx?id=369511] recently highlights, this
approach is a lousy strategy.

Most of the problems have to do with the nature of these little beasts, which are much less liquid
than their larger brethren. The best ETFs hold equities that trade in efficient, deep, and liquid
markets -- everything that microcaps can't provide.

I'm a fan of using ETFs for sector investing or quick-and-easy hedges on the short side, but for
microcaps Morningstar warns that these ETFs are “some of the worst in the world.” They explain
that “microcap ETFs fall prey to nearly every weakness in the ETF structure, which devastates
their returns.”

Let's be real. Using ETFs to invest in microcaps gives investors the sensation of participating in
this market segment. In reality, though, investors are saddled with a large basket of small stocks
that underperform even relative to the indexes they're tracking. As Morningstar points out, "after
controlling for the ETFs' risk exposures, such as size, value and momentum, they trailed their true
benchmarks by about 6% annually."

What's even more disturbing is that microcap ETFs have never been more popular. On the back
of great performance since September, investors have poured in over $300 million into the four
microcap ETFs (the most ever!), according to Morningstar.

By now you're probably thinking that microcap mutual funds must offer a much better alternative
to ETFs. Not so. Exploitive costs aside, most microcap funds invest in 50 to 100, and sometimes
more companies, and that dilutes the best strategic advantages (e.g. focus and leverage) of
investing in small stocks.

The truth is that microcaps are not well-suited for passive investors. For any serious investor who
wants to have 5% to 20% exposure to microcaps in his or her portfolio, you've got to be prepared
to do your homework because there are no ready-made shortcuts. To take advantage of the
often staggering inefficiencies and opportunities in the microsphere, you have to do the research,
monitor your investments, and actively manage this portion of your portfolio.

Subscribe to Functional Inspiration: http://www.levinesmicrocapinvestor.com/RSS/Articles.xml

MicroCap Investor delves deep into the world of small stocks to identify big winners. Levine
targets innovative companies on the path of the new and revolutionary, developing technologies
that disrupt entrenched markets to create tremendous value.

About Josh Levine and Levine's MicroCap Investor www.levinesmicrocapinvestor.com

Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing
in top-performing micro- and small-cap stocks. He excels at assessing management teams and
evaluating new innovations and their impact on corporate valuations.

In 2002 he joined independent investment-research boutique ChangeWave Research, where he
was editor of ChangeWave MicroCap Investor since 2004, becoming Levine's MicroCap Investor
in 2010. He has been editor of the flagship ChangeWave Investing since 2007.

Levine is also senior analyst for ChangeWave Research. Through its survey network comprised
of 25,000 members, ChangeWave tracks the rate of change in corporate and consumer demand
trends and provides the results through an institutional research subscription service. Its
macroeconomic research is among the best on Wall Street.
More on Levine’s bio: http://www.levinesmicrocapinvestor.com/aboutus/

Learn more about subscribing to Levine’s MicroCap Investor: http://
www.levinesmicrocapinvestor.com/subscriptions/order/

InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to
provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com
team operates this web site and manages the administration and marketing for MicroCap
Investor.

InvestorIdeas.com is a leading investment and industry research portal, with resources covering
high-growth sectors including technology, biotech and cleantech.

Levine’s MicroCap Investor

Contact us
http://www.levinesmicrocapinvestor.com/contactus/

Nanotechnology Stocks; mPhase Technical Research Published in the Journal of Porous Materials

NORWALK, CT - February 14, 2011 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB:XDSL), a leader in the development of Smart Surfaces and advanced battery technologies, today announced that an article describing research they are conducting in developing techniques for giving hydrophobic and superhydrophobic repelling properties to non-silicon materials, such as glass fibers, for use in potential applications or devices benefiting from microfluidic delivery and energy storage, have been showcased in a recent issue of the Journal of Porous Materials.

The Journal of Porous Materials is an international, interdisciplinary periodical focused on the rapid publication of high quality, peer-reviewed papers on synthesis, processing, characterization and evaluation of all porous materials. The journal addresses the dramatic pace of progress in the design and synthesis, characterization and property evaluation of porous materials for catalysis, separations and sensors. The title of the article, "Preparation and Electrowetting Transitions on Superhydrophobic/Hydrophilic Bi-layer Structures," presents a simplified and cost reduced method of preparing porous superhydrophobic materials using glass fiber materials and special coatings developed by the mPhase team. The materials presented by the mPhase team show all of the attributes of the previously reported Si-based materials, while showing new and improved characteristics such as flexible, compliant nature, simple fabrication route from the widely used, commercially available glass fiber materials and, potentially, dramatically reduced fabrication cost. The article goes on to describe how the structures of the filter material provide for the "surface roughness" on the micro and nano-scale, which is required for achieving a superhydrophobic state. The article demonstrates how this approach can be used to prepare fibrous, non-silicon materials as potential approaches for separating mixtures such as water and gasoline or oil, while repelling the water and preventing it from permeating through the fiber material and as flexible substrates for lab-on-a-chip analytical devices.
The article on the bi-layer materials can be found online at the publisher�s web site with the following URL: http://dx.doi.org/10.1007/s10934-010-9406-0. A courtesy copy of the article can also be found on the mPhase web site at http://www.mphasetech.com/pdfarticles/mphase_hydrophilic.pdf
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab on a chip analytic systems, self cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.
In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio. http://www.mpowertech.com
More information about the company can be found at http://www.mPhaseTech.com.
Forward Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company s products in the market; the Company s success in technology and product development; the Company s ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company s SEC filings, including the financial statements and related information contained in the Company s SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
mPhase Technologies, Inc. 973 256 3737

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Biotech/ Pharma Stock Trading Alert; BioSante Pharmaceuticals Inc up on News

Point Roberts, WA. –February 14, 2011 (Investorideas.com Energy stocks Newswire) -
www.InvestorIdeas.com and its leading Biotech investor portals, announces a technical stock
trading alert for BioSante Pharmaceuticals Inc (NASDAQ:BPAX). The stock is trading at $2.41,
up 0.10 (4.33%), trading as high as $2.53 in morning trading.

Recent News: BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Positive LibiGel Safety
Data in Phase III Program

“LINCOLNSHIRE, Ill. - February 14, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX),
presented positive safety data in its ongoing LibiGel Phase III clinical development program, at
the annual meeting of ISSWSH on February 12, 2011.

BioSante reported that with 2,869 women enrolled and over 3,000 women-years of exposure
in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17
adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately
0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27
percent.

Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-
agreed protocol, without modifications including continued enrollment of new subjects. This was
the recommendation of the independent Data Monitoring Committee (DMC) based on its 5th
unblinded review of all study safety data. LibiGel is in development for the treatment of female
sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal
women, for which there is no FDA-approved product.”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/02142.asp

Recent News: BioSante Pharmaceuticals, Inc. To Present LibiGel®
Safety Study Update At BIO CEO & Investor Conference

“LINCOLNSHIRE, Illinois (February 14, 2011) – BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the
Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take
place February 14-15, 2011 at the Waldorf-Astoria in New York.

Stephen M. Simes, BioSante’s president & CEO, will speak today, Monday February 14, 2011
at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel®
(testosterone gel) Phase III clinical development program including safety data. A live audio
webcast of Mr. Simes’ remarks may be accessed at: http://www.veracast.com/webcasts/bio/

ceoinvestor2011/16113289.cfm .”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/02141.asp

More info: About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female
sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal
testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III
clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol
Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have
been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other
products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to
Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante
patented technology. The company also is seeking opportunities for its other technologies.
Additional information is available online at: www.biosantepharma.com.

Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

Contact BioSante Pharmaceuticals

For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com

Investorideas.com Disclosure, Disclaimer/ BPAX is a paid advertising client on
Investorideas.com. (one thousand per month)

Disclaimer: The following news is paid for by BPAX (three thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make
recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Oil and Gas Stocks; Aroway Energy Inc. Executes Option on Additional 29 Sections

CALGARY, ALBERTA - February 14, 2011 (Investorideas.com energy stocks newswire) � Aroway Minerals Inc. (TSX-V:ARW; PINK:ARWJF) (www.arowayenergy.com) (the "Company") is pleased to announce that the Company and its joint venture partner ("Partner") have entered into a rolling farmout agreement ("Agreement") with a private oil and gas company (the "Farmor") with access to 29 sections, of 3D seismically defined land (the "Lands") located within the Company's and its Partner's core area of interest in the Peace River Arch area of Northern Alberta.

The terms of the agreement commit the Partnership to drill 1 well on the Farmor's Lands before February 28, 2011, and a second well on the Lands before August 1st, 2011. Each well drilled on the Lands earns the spacing unit. The Partnership will also have the option to continue the Agreement by committing to drill a well on the undrilled Lands every 90 days from the rig release of the previously drilled well, subject to weather and ground conditions. Together with its partner, the Company also purchased approximately 45 square kms of proprietary 3D data which covers a substantial portion of the Agreement Lands, for $330,000 net to Aroway. The Company's Partner has already identified several drillable prospects within the Agreement Lands.
Aroway paid 50% of the total consideration for the rolling option and the 3D seismic, and will pay 50% of all costs associated with the development of the Lands to earn 50% of all revenue generated from these acquired Lands. The Farmor will retain a variable royalty depending on the location of the drilling target that will range from 7.5% to 12.5%. The execution of the rolling option agreement gives Aroway access to a total of 79 sections of land in the Company's Core operating area within the Peace River Arch of northern Alberta.
Chris Cooper, President of Aroway, commented, "The execution of the option agreement enables us to become a fast growing player in our core area. Aroway has grown from a 4 section farmout to having access to 79 sections in one of the hottest regions of Northern Alberta in just 4 months. We look forward to continued exploration success in 2011."
Aroway is also very pleased to report that workover operations on the Partnership's recent well acquired through the 5 section acquisition announced on January 31, 2011 have been completed. Current production from the well has been increased 250% from 20 boe/day to 50 boe/day (25 boe/day net to Aroway).
About Aroway Energy Inc.
Aroway Energy Inc. is a Western Canadian junior oil and gas production and exploration company participating in "non-operated" Peace River Arch oil and gas exploration prospects, through a joint venture partnership. Aroway is currently producing approximately 225 boe/day of oil, gas liquids and gas net to Aroway
ON BEHALF OF AROWAY ENERGY INC.
Chris Cooper, President
BOEs may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf: 1bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Judy-Ann Pottinger
Aroway Energy Inc.
(604) 304-4090 or Cell: (604) 617-5290
(604) 909-2679 (FAX)
jpottinger@arowayenergy.com
www.arowayenergy.com
(647) 258-3311 or Toll Free: (888) 258-3323
Investor Cubed Inc.
(416) 363-7977 (FAX)
info@investor3.ca
Disclosure: ARW is a paid advertising client on Investorideas.com and our energy, natural gas, and oil and gas portals.

Visit the ARW showcase profile at Investorideas.com
Request News and Info on ARW

Electric Car Stocks Investor Alert; EVCARCO Breaks Through 52 Week High - Trading up 40.35%


February 14, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks news and trading.
Electric car stock EVCARCO (OTCBB: EVCA) (www.evcarco.com) broke through its 52 week high in Friday�s market and is trading at $0.08, up 0.0230 (40.35%) in early morning trading. Volume as of this release was over 2.5 million shares traded.
Company Snapshot
EVCARCO (OTCBB: EVCA) (www.evcarco.com) is an automotive retail group dedicated to deploying a franchised coast-to-coast network of environmentally friendly dealerships and vehicles.

Market Snapshot

• Dow 12,247.08 -26.18 -0.21%
• Nasdaq 2,814.36 +4.92 +0.18%
• S&P 500 1,329.22 +0.07 +0.01%
• 10 Yr Bond (%) 3.6330% -0.0130
• Oil 85.59 +0.01 +0.01%

Gold 1,363.70 +3.80 +0.28%
Research electric car stocks and green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a former showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com

Biotech/Pharma Stock News; BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program


LINCOLNSHIRE, Ill. - February 14, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), presented positive safety data in its ongoing LibiGel Phase III clinical development program, at the annual meeting of ISSWSH on February 12, 2011.

BioSante reported that with 2,869 women enrolled and over 3,000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent.
Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-agreed protocol, without modifications including continued enrollment of new subjects. This was the recommendation of the independent Data Monitoring Committee (DMC) based on its 5th unblinded review of all study safety data. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
"Once again, the DMC has recommended that the safety study continue as per the FDA-agreed protocol, without modification as there were no general or specific safety issues based on their unblinded review of adverse events. In addition, the low number of CV events to date is consistent with the safety of testosterone in this population," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante. "Once the DMC determines that there are enough subjects enrolled for statistical significance, enrollment of new subjects will be complete. The protocol allows up to 4,000 women to be enrolled, however, the DMC may recommend completion of enrollment at any time between the current enrollment and the 4,000 women maximum."
Subjects have been enrolled in this study for an average of 12.5 months. More than 1,000 subjects have been enrolled in the study for more than a year and over 550 subjects for more than two years. The periodic reviews by the DMC are based on their mandate in accordance with FDA agreement on protocol-defined study oversight. BioSante's objective is to submit the LibiGel NDA for a product launch in 2012.
"LibiGel remains the only product in the world in Phase III clinical development for the treatment of HSDD," said Stephen M. Simes, BioSante's president & CEO. "We expect to announce completion of enrollment in both Phase III efficacy trials in the near-future," Mr. Simes continued. "With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD, also referred to as FSD, in menopausal women."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has enrolled 2,869 women, with a maximum of 4,000 patients to be enrolled. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as �will,� �potential,� �could,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present LibiGel Safety Study Update at BIO CEO & Investor Conference

LINCOLNSHIRE, Ill. - February 14, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15, 2011 at the Waldorf-Astoria in New York.

Stephen M. Simes, BioSante�s president & CEO, will speak today, Monday February 14, 2011 at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel� (testosterone gel) Phase III clinical development program including safety data. A live audio webcast of Mr. Simes� remarks may be accessed at: http://www.veracast.com/webcasts/bio/ceoinvestor2011/16113289.cfm
A webcast replay will be available for 90 days beginning one hour after conclusion of the live event.
About The BIO CEO & Investor Conference
Now in its thirteen year, the BIO CEO & Investor Conference 2011 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. This year�s conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities. For more information, visit www.ceo.bio.org.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

AeroDrive, Inc. completes design of 2MW Continuously Variable Transmission for Utility-scale Wind Turbines

February 14, 2011 (investorideas.com renewable energy/green news) AeroDrive, Inc. has completed design work on a 2MW capacity continuously variable transmission (CVT) for utility-scale wind turbines, that utilizes our patented technology. This 2MW CVT is a full scale proof-of-technology test rig that is being prepared for a proposed qualification bench test effort at the U.S. National Renewable Energy Labs facility in Golden, Colorado.

Our reliable, high-efficiency CVT design allows the use of synchronous AC generators in utility-scale wind turbine drivetrains of 10MW or more. Our CVT, with its high frequency control response and wide range of drive ratios, extends wind turbine operating limits, provides effective rotor and drivetrain gust load alleviation, provides higher quality power to the grid, and significantly reduces the turbine's lifetime Cost Of Energy (COE).
AeroDrive's mechanical CVT also provides a more efficient and cost effective alternative to the expensive license fees required for using a less efficient DFIG-type variable speed design.
For more information contact AeroDrive, Inc.
information@aerodrive-inc.com